TW202143970A - 用於治療高風險之非肌肉侵犯性膀胱癌的fgfr酪胺酸激酶抑制劑 - Google Patents

用於治療高風險之非肌肉侵犯性膀胱癌的fgfr酪胺酸激酶抑制劑 Download PDF

Info

Publication number
TW202143970A
TW202143970A TW110105372A TW110105372A TW202143970A TW 202143970 A TW202143970 A TW 202143970A TW 110105372 A TW110105372 A TW 110105372A TW 110105372 A TW110105372 A TW 110105372A TW 202143970 A TW202143970 A TW 202143970A
Authority
TW
Taiwan
Prior art keywords
fgfr
inhibitor
patient
fgfr3
erdatinib
Prior art date
Application number
TW110105372A
Other languages
English (en)
Chinese (zh)
Inventor
曼尼希 蒙加
馬哈迪 拜格
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202143970A publication Critical patent/TW202143970A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110105372A 2020-02-12 2021-02-17 用於治療高風險之非肌肉侵犯性膀胱癌的fgfr酪胺酸激酶抑制劑 TW202143970A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062975547P 2020-02-12 2020-02-12
US62/975,547 2020-02-12
US202063018914P 2020-05-01 2020-05-01
US63/018,914 2020-05-01
US202063118475P 2020-11-25 2020-11-25
US63/118,475 2020-11-25

Publications (1)

Publication Number Publication Date
TW202143970A true TW202143970A (zh) 2021-12-01

Family

ID=74666675

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110105372A TW202143970A (zh) 2020-02-12 2021-02-17 用於治療高風險之非肌肉侵犯性膀胱癌的fgfr酪胺酸激酶抑制劑

Country Status (14)

Country Link
US (1) US20230110113A1 (https=)
EP (1) EP4103185A1 (https=)
JP (1) JP2023513704A (https=)
KR (1) KR20220140781A (https=)
CN (1) CN115103678A (https=)
AU (1) AU2021220285A1 (https=)
BR (1) BR112022015827A2 (https=)
CA (1) CA3162962A1 (https=)
IL (1) IL295514A (https=)
JO (1) JOP20220182A1 (https=)
MX (1) MX2022009905A (https=)
PH (1) PH12022552093A1 (https=)
TW (1) TW202143970A (https=)
WO (1) WO2021160764A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312063A (en) * 2021-10-12 2024-06-01 Taris Biomedical Llc Ardafitinib formulations and systems for intravesical administration
KR20240145513A (ko) * 2022-02-18 2024-10-07 타리스 바이오메디컬 엘엘씨 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템
KR20250143348A (ko) * 2023-02-13 2025-10-01 타리스 바이오메디컬 엘엘씨 방광암 치료에 사용하기 위한 방광내 투여용 에르다피티닙
EP4665341A1 (en) * 2023-02-13 2025-12-24 Janssen Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
CN120731077A (zh) * 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
KR102470456B1 (ko) * 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
HUE062453T2 (hu) * 2017-02-06 2023-11-28 Janssen Pharmaceutica Nv Rákbetegség kezelése
TWI798199B (zh) * 2017-02-06 2023-04-11 比利時商健生藥品公司 癌症治療

Also Published As

Publication number Publication date
AU2021220285A1 (en) 2022-10-06
IL295514A (en) 2022-10-01
US20230110113A1 (en) 2023-04-13
JOP20220182A1 (ar) 2023-01-30
BR112022015827A2 (pt) 2022-10-04
KR20220140781A (ko) 2022-10-18
CA3162962A1 (en) 2021-08-19
JP2023513704A (ja) 2023-04-03
WO2021160764A1 (en) 2021-08-19
EP4103185A1 (en) 2022-12-21
CN115103678A (zh) 2022-09-23
PH12022552093A1 (en) 2023-11-29
MX2022009905A (es) 2022-08-25

Similar Documents

Publication Publication Date Title
TW202143970A (zh) 用於治療高風險之非肌肉侵犯性膀胱癌的fgfr酪胺酸激酶抑制劑
AU2020253054B2 (en) FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
JP2025156297A (ja) 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
US20250000858A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
TW202448471A (zh) 用於治療高風險非肌層浸潤性膀胱癌之ｆｇｆｒ酪胺酸激酶抑制劑
HK40081735A (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40126446A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EA052400B1 (ru) Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы